Opinion

Video

The Role of PSA Doubling Time in Risk Assessment

Author(s):

Stephen J. Freedland, MDEleni Efstathiou, MD, PhD

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

  1. Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment?
    1. At what PSA doubling time thresholds do treatment recommendations change?
    2. How reliable is PSA doubling as a biomarker versus imaging or other tests?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
US FDA
September 3rd 2024

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
August 27th 2024

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Kara N. Maxwell, MD, PhD, director, Men and BRCA Program, Basser Center, associate professor, medicine (hematology-oncology), Perelman School of Medicine, University of Pennsylvania
August 20th 2024

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 16th 2024

Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC